Ecomectin 18.7mg/g Oral Paste for Horses
Table of contents
Ecomectin 18.7 mg/g Oral Paste for Horses is a white homogenous paste containing ivermectin. Ivermectin is a member of the macrocyclic lactone class of endectocides. Ecomectin 18.7 mg/g Oral Paste for Horses is intended to be used in horses for the treatment of nematode or arthropod infections caused by Strongylus vulgaris, Strongylus edentatus, Strongylus equinus, Small strongyles (including benzimidazole resistant strains): Cyathostomum spp, Cylicocyclus spp., Cylicodontophorus spp., Cylicostephanus spp., Gyalocephalus spp., Ascarids: Parascaris equorum, Pinworms: Oxyuris equim, Neck threadworms: Onchocerca spp, Stomach bots: Gasterophilus spp
A marketing authorisation for Ecomectin 18.7 mg/g Oral Paste for Horses was previously granted to Eco Animal Health Ltd in Ireland on 10 November 2006.
A mutual recognition procedure was started on 1 February 2007. The Reference Member State was Ireland and the Concerned Member States were Belgium, Cyprus, Czech Republic, Germany, Denmark, Greece, Spain, Finland, France, Hungary, Italy, the Netherlands, Norway, Portugal, Sweden and the United Kingdom. The product was accepted by the Belgium, Cyprus, Czech Republic, Denmark, Greece, Spain, Finland, France, Hungary, Italy, the Netherlands, Norway, Portugal, Sweden and the United Kingdom. Concerns were raised by Germany regarding that this veterinary medicinal product may present a potential serious risk to public health on the following grounds:
- An environmental risk was detected during the risk assessment Phase II Tier A for dung fauna organisms;
- No adequate data for Tier B were provided by the applicant to assess the long-term effects on dung fauna organisms caused by the use of the product.
On 4 July 2007, Ireland notified EMEA that the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Veterinary (CMD(v)) failed to reach an agreement regarding Ecomectin 18.7 mg/g Oral Paste for Horses and its associated names. Pursuant to Article 33(4) of Council Directive 2001/82/EC, as amended, the matter has been referred to the CVMP.
The scope of the referral was to whether the environmental risk detected during the risk assessment Phase II Tier A for dung fauna organisms would present a potential serious risk to public health.
The arbitration procedure started on 11 July 2007 with the adoption of list of questions. The rapporteur was Dr. B. Urbain and the co-rapporteur was Prof. S. Srčič. The Marketing Authorisation Holder provided written explanations on 12 September 2007. Oral explanations were presented on 10 October 2007 by the Marketing Authorisation Holder to the Committee.
During its 6-8 November 2007 meeting, the CVMP, in light of the overall data submitted and the scientific discussion within the Committee, adopted by consensus an opinion that since the product is intended for use in a minor species (horses) that is reared and treated similarly to a major species, the conclusions on the Environmental Risk Assessment of the major species apply, and therefore the product should be exempt from providing a Phase II assessment and no risk mitigation measures should be included in the SPC of the product.
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II.
The final opinion was converted into a Decision by the European Commission on 17 January 2008.
Ecomectin 18.7mg/g Oral Paste for Horses
|International non-proprietary name (INN) or common name||
European Commission final decision
Mutual-recognition and decentralised referral: initiated because of disagreement between Member States within the framework of the mutual-recognition or decentralised procedure.
|EC decision date||
Opinion following an Article 33 referral for Ecomectin 18.7 mg/g Oral Paste for Horses and its associated names International Non-Proprietary Name (INN): Ivermectin: Background information (PDF/75.17 KB)Adopted
First published: 19/02/2008
Last updated: 19/02/2008
Ecomectin 18.7mg/g Oral Paste for Horses - Article 33 Referral - Annex I, II, III (PDF/60.71 KB)Adopted
First published: 21/02/2008
Last updated: 21/02/2008
Description of documents published
Please note that some of the listed documents apply only to certain procedures.
- Overview - lay-language summary of the stage of the procedure
- Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
- List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
- Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
- List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
- List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. veterinary healthcare professionals, farmers, academia) (if applicable)
- Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
- Scientific conclusions – scientific conclusions of CVMP
- Divergent positions – divergent positions of the CVMP members (if applicable)
- Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
- Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
- Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)